Skip to main content

Table 2 Univariate and multivariate Cox regression analysis of overall survival of the two cohorts

From: B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients

 

Univariate

Multivariate

HR

95%CI

P

HR

95%CI

P

Training cohort

 Age(continuous)

1.006

0.986 ~  1.025

0.574

1.004

0.985 ~  1.024

0.661

 Gender(male vs female)

0.697

0.383 ~  1.268

0.240

   

 B4GALT1(high vs low)

1.849

1.126 ~  3.035

0.016

1.773

1.075 ~  2.924

0.026

 CCI(≥2 vs ≤1)

1.154

0.712 ~  1.872

0.563

   

 LVI(present vs absent)

1.449

0.898 ~  2.339

0.131

   

 pN(N+ vs N-)

1.651

0.718 ~  3.795

0.240

   

 pT stage

  pT3 vs pT2

1.063

0.625 ~  1.808

0.824

   

  pT4 vs pT2

1.765

1.005 ~  3.100

0.049

   

 TNM stage

  III vs II

1.278

0.797 ~  2.051

0.312

1.220

0.759 ~  1.961

0.414

  IV vs II

1.877

0.784 ~  4.492

0.159

1.636

0.680 ~  3.938

0.274

Validation cohort

 Age(continuous)

1.062

1.020 ~  1.105

0.004

1.050

1.006 ~  1.095

0.025

 Gender(male vs female)

0.929

0.369 ~  2.337

0.876

   

 B4GALT1(high vs low)

2.158

1.187 ~  3.923

0.012

1.862

1.016 ~  3.413

0.046

 CCI(≥2 vs ≤1)

1.847

0.993 ~  3.438

0.054

   

 LVI(present vs absent)

1.926

1.073 ~  3.456

0.029

1.060

0.458 ~  2.452

0.893

 pN(N+ vs N-)

1.626

1.194 ~  2.213

0.002

   

 pT stage

  pT3 vs pT2

2.708

1.426 ~  5.142

0.003

   

  pT4 vs pT2

2.517

0.967 ~  6.550

0.060

   

 TNM stage

  III vs II

3.291

1.471 ~  7.362

0.004

2.555

1.126 ~  5.796

0.026

  IV vs II

6.290

2.874 ~  13.768

< 0.001

5.230

1.962 ~  13.943

0.001